Neurotech International Ltd has released a press release.
Neurotech receives $4.73m R&D Tax Incentive Refund
Filed with ASX ·
6ix hasn’t read this filing yet.
Neurotech International Ltd. on 6ix
Story so far
Earlier from Neurotech International
- US FDA Rare Pediatric Disease Designation in Rett syndrome
- Appendix 4E & Annual Report to shareholders
- Positive Human PK Study Results for NTI164
- NTI164 Preclinical Toxicology Studies Update
- Appendix 4D and Half Year Accounts
Later from Neurotech International
- Trading Halt
- Binding Commitments Received for a $4 Million Placement
- Quarterly Activities/Appendix 4C Cash Flow Report
- Approval received for NTI164 Phase 3 Clinical Study in ASD
- Positive 90-day GLP toxicology study results in non-rodents
Follow Neurotech International into a list and get an email when it puts out news.
Follow Neurotech International